David Ricks, Eli Lilly CEO (Jeenah Moon/Bloomberg via Getty Images)
July 2, 2024 02:02 PM EDTUpdated 03:20 PM
Pharma
FDA+

Up­dat­ed: Eli Lil­ly wins long-await­ed ap­proval for Alzheimer’s drug

Ryan Cross

Senior Science Correspondent

Af­ter decades of try­ing to de­vel­op a treat­ment for Alzheimer’s dis­ease, Eli Lil­ly has fi­nal­ly won FDA ap­proval for its drug do­nanemab …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

Pfiz­er CEO says op­por­tu­ni­ties with Trump ‘clear­ly out­weigh’ the risks for phar­ma

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times